Human pegivirus-1 infection in kidney transplant recipients: A single-center experience.

Autor: Savassi-Ribas F; Department of Microbiology and Parasitology, Biomedical Institute, Fluminense Federal University, Niterói, Brazil., Pereira JG; Laboratory of Molecular Virology, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Rio de Janeiro, Brazil., Horta MAP; BSL-3 Platform, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Rio de Janeiro, Brazil., Wagner TCS; Service of Renal Transplantation, Rio de Janeiro State Center of Transplantation, São Francisco na Providência de Deus Hospital, Rio de Janeiro, Rio de Janeiro, Brazil., Matuck TA; Service of Renal Transplantation, Rio de Janeiro State Center of Transplantation, São Francisco na Providência de Deus Hospital, Rio de Janeiro, Rio de Janeiro, Brazil., Monteiro de Carvalho DB; Service of Renal Transplantation, Rio de Janeiro State Center of Transplantation, São Francisco na Providência de Deus Hospital, Rio de Janeiro, Rio de Janeiro, Brazil., Mello FCA; Laboratory of Viral Hepatitis, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Rio de Janeiro, Brazil., Varella RB; Department of Microbiology and Parasitology, Biomedical Institute, Fluminense Federal University, Niterói, Brazil., Soares CC; Laboratory of Molecular Virology, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Rio de Janeiro, Brazil.
Jazyk: angličtina
Zdroj: Journal of medical virology [J Med Virol] 2020 Dec; Vol. 92 (12), pp. 2961-2968. Date of Electronic Publication: 2020 Mar 20.
DOI: 10.1002/jmv.25764
Abstrakt: Kidney transplantation is the treatment of choice for patients with end-stage renal disease. In the posttransplant period, the induced immunosuppression leads to an increased risk of developing infectious diseases, a leading cause of death after kidney transplantation. Human pegivirus-1 (HPgV-1) is considered a nonpathogenic human virus and is highly frequent in individuals parenterally exposed, however, its impact on kidney transplantation outcome is poorly understood. Given the scarcity of epidemiological data for this infection on organ recipients in Brazil, we conducted a study in a single center for kidney transplantation in Rio de Janeiro, aiming to determine HPgV-1 prevalence and genotypic distribution. Serum samples from 61 renal recipients, followed up for the first year after transplantation, were evaluated for viral RNA and genotypes were determined by sequencing of the 5'-untranslated region. HPgV-1 RNA was detected in 36.1% (22/61) of patients. Genotype 2 was the most commonly found (80.9%), followed by genotypes 3 (9.5%), 1, and 5, in 4.8% each. Statistical comparisons did not reveal any significant impact of HPgV-1 in patient outcome. Further epidemiologic studies are needed to understand if immunosuppression may interfere in HPgV-1 persistence rates and if viremia might impact graft dysfunction rates in kidney recipients.
(© 2020 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: